Press Releases - Emmaus Medical, Inc.

OTC Markets Group Welcomes Emmaus Life Sciences, Inc. to OTCQXSeptember 08, 2021

OTC Markets Group Inc. (OTCQX: OTCM) today announced Emmaus Life Sciences, Inc. (OTCQX: EMMA) has qualified to trade on the OTCQX® Best Market. Emmaus Life Sciences, Inc. upgraded to OTCQX from the Pink® market.

Emmaus Life Sciences Reports Financial Results for the Six Months Ended June 30, 2021September 02, 2021

Emmaus Life Sciences, Inc. (OTC: EMMA) announced financial results for the six months ended June 30, 2021. As a result, the company is now current in its Securities and Exchange Commission (SEC) reporting obligations.

Emmaus Life Sciences Announces Bahrain Temporary License of EndariAugust 17, 2021

License Permits Importation and Early Access to Patients Pending Marketing Authorization

Emmaus Life Sciences Provides SEC Reporting UpdateAugust 10, 2021

2020 Financial Statements Restated to Reflect Increase in Net Income Attributable to Change in Equity Method Investment in Japanese Affiliate. Amended and Restated Form 10-K Includes Complete Restated Financial Statements and Currently Dated, Unqualified Audit Report.

Texas Adds Endari to Latest Preferred Drug ListAugust 02, 2021

Emmaus Life Sciences, Inc. (OTC: EMMA) announced today that Endari has been included on the Preferred Drug List published on July 29, 2021, by Texas Health and Human Services (THHS).